Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Best Supportive Care in Resistant GIST
NCT00471328Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Mar 2007; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00471328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471328.